D. Neri

Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells

This study develops anti-CD117 CAR T cells with a safety switch to target and eliminate acute myeloid leukemia and hematopoietic stem cells in preclinical models.

A mass spectrometry-based method for the determination of in vivo biodistribution of tumor targeting small molecule-metal conjugates

The paper develops a mass spectrometry-based method to quantify tumor-targeting small molecule-metal conjugates and validates it against radioactive biodistribution data.

A novel dimeric FAP-targeting small molecule-radio conjugate with high and prolonged tumour uptake

This paper develops a dimeric FAP-targeting radioligand with prolonged tumour uptake and improved tumour-to-organ ratio, showing potent anti-tumour efficacy in preclinical models.

Engineering murine GITRL for antibody-mediated delivery to tumor-associated blood vessels

This paper develops GITRL-fusion proteins targeting tumor vasculature but finds they fail to show anti-tumor activity in preclinical models.

Antibody-based delivery of Interleukin-9 to neovascular structures: therapeutic evaluation in cancer and arthritis

This study evaluates the therapeutic potential of IL9 delivered via antibody-based fusion proteins in cancer and arthritis models, finding modest anti-tumor activity but no benefit in arthritis.

Sortase-mediated site-specific modification of interleukin-2 for the generation of a tumor targeting acetazolamide-cytokine conjugate

This paper develops a tumor-targeting cytokine conjugate using Sortase A-mediated site-specific modification of interleukin-2 with acetazolamide, targeting carbonic anhydrase IX.

Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX

This study shows that combining SMDCs targeting carbonic anhydrase IX with immunotherapy enhances anticancer activity in mouse models of renal cell carcinoma and colorectal cancer.

Antibody-mediated delivery of LIGHT to the tumor boosts Natural Killer cells and delays tumor progression

This paper develops a LIGHT-based fusion protein that accumulates in tumors and enhances Natural Killer cell activity, slowing tumor growth in mouse models.

An engineered 4-1BBL fusion protein with ''activity-on-demand''

This paper describes an engineered antibody-cytokine fusion protein that activates only upon antigen binding, showing potent anti-tumor activity with reduced toxicity in mouse models.

The immunocytokine L19-TNF eradicates Sarcomas in combination with Chemotherapy or with immune check-point inhibitors

The paper shows that combining the immunocytokine L19-TNF with chemotherapy or immune checkpoint inhibitors improves tumor remission in a sarcoma mouse model.

A universal reporter cell line for bioactivity evaluation of engineered cytokine products

The paper develops a universal reporter cell line system for evaluating bioactivity of engineered cytokine products and identifies a mechanism for cytokine potentiation.

Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice

This study compares bolus and fractionated administration of two antibody-cytokine fusions in mice, finding that fractionation reduces toxicity for one but increases efficacy for another.

Immunotherapy of CT26 murine tumors is characterized by an oligoclonal response against the AH1 tumor rejection antigen

This study shows that immunotherapy of CT26 tumors using cytokine-based treatments leads to an oligoclonal T cell response targeting the AH1 antigen.

A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis

This study develops a human monoclonal antibody targeting A33, showing efficacy in inhibiting colorectal cancer metastasis in vivo.

A novel fully-human potency-matched dual cytokine-antibody fusion protein targets carbonic anhydrase IX in renal cell carcinomas

This paper describes the development and characterization of a dual cytokine-antibody fusion protein targeting carbonic anhydrase IX in renal cell carcinomas, showing tumor localization and growth inhibition.

Targeted enhancement of the therapeutic window of L19-TNF by transient and selective inhibition of RIPK1-signaling cascade

This study shows that transient RIPK1 inhibition increases the tolerated dose of L19-TNF while preserving its antitumor effects and tumor targeting.

An antibody-tumor necrosis factor fusion protein that synergizes with oxaliplatin for treatment of colorectal cancer

This paper describes a fusion protein that synergizes with oxaliplatin to treat colorectal cancer, achieving tumor eradication in 40% of mice.

The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune check-point inhibitors

This paper describes a fusion protein that delivers interleukin-12 to tumors, enhancing NK and CD8+ T cell activity and synergizing with checkpoint inhibitors.